Griffin JD - Search Results

1

Drug resistance in mutant FLT3-positive AML.

Weisberg E, Sattler M, Ray A, Griffin JD. Weisberg E, et al. Among authors: griffin jd. Oncogene. 2010 Sep 16;29(37):5120-34. doi: 10.1038/onc.2010.273. Epub 2010 Jul 12. Oncogene. 2010. PMID: 20622902 Review.

2

Mechanisms of resistance imatinib (STI571) in preclinical models and in leukemia patients.

Weisberg E, Griffin JD. Weisberg E, et al. Among authors: griffin jd. Drug Resist Updat. 2001 Feb;4(1):22-8. doi: 10.1054/drup.2001.0180. Drug Resist Updat. 2001. PMID: 11512149 Review.

3

Smac mimetics: implications for enhancement of targeted therapies in leukemia.

Weisberg E, Ray A, Barrett R, Nelson E, Christie AL, Porter D, Straub C, Zawel L, Daley JF, Lazo-Kallanian S, Stone R, Galinsky I, Frank D, Kung AL, Griffin JD. Weisberg E, et al. Among authors: griffin jd. Leukemia. 2010 Dec;24(12):2100-9. doi: 10.1038/leu.2010.212. Epub 2010 Sep 16. Leukemia. 2010. PMID: 20844561 Free PMC article.

4

Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors.

Weisberg E, Liu Q, Nelson E, Kung AL, Christie AL, Bronson R, Sattler M, Sanda T, Zhao Z, Hur W, Mitsiades C, Smith R, Daley JF, Stone R, Galinsky I, Griffin JD, Gray N. Weisberg E, et al. Among authors: griffin jd. Leukemia. 2012 Oct;26(10):2233-44. doi: 10.1038/leu.2012.96. Epub 2012 Apr 3. Leukemia. 2012. PMID: 22469781 Free PMC article.

5

The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ABL and p210BCR/ABL to the phosphatidylinositol-3' kinase pathway.

Sattler M, Salgia R, Okuda K, Uemura N, Durstin MA, Pisick E, Xu G, Li JL, Prasad KV, Griffin JD. Sattler M, et al. Among authors: griffin jd. Oncogene. 1996 Feb 15;12(4):839-46. Oncogene. 1996. PMID: 8632906

6

The phosphatidylinositol polyphosphate 5-phosphatase SHIP and the protein tyrosine phosphatase SHP-2 form a complex in hematopoietic cells which can be regulated by BCR/ABL and growth factors.

Sattler M, Salgia R, Shrikhande G, Verma S, Choi JL, Rohrschneider LR, Griffin JD. Sattler M, et al. Among authors: griffin jd. Oncogene. 1997 Nov 6;15(19):2379-84. doi: 10.1038/sj.onc.1201422. Oncogene. 1997. PMID: 9393882

7

Expression of the focal adhesion protein paxillin in lung cancer and its relation to cell motility.

Salgia R, Li JL, Ewaniuk DS, Wang YB, Sattler M, Chen WC, Richards W, Pisick E, Shapiro GI, Rollins BJ, Chen LB, Griffin JD, Sugarbaker DJ. Salgia R, et al. Among authors: griffin jd. Oncogene. 1999 Jan 7;18(1):67-77. doi: 10.1038/sj.onc.1202273. Oncogene. 1999. PMID: 9926921

8

Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines.

Weisberg E, Griffin JD. Weisberg E, et al. Among authors: griffin jd. Blood. 2000 Jun 1;95(11):3498-505. Blood. 2000. PMID: 10828035 Free article.

9

Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571.

Wang WL, Healy ME, Sattler M, Verma S, Lin J, Maulik G, Stiles CD, Griffin JD, Johnson BE, Salgia R. Wang WL, et al. Among authors: griffin jd. Oncogene. 2000 Jul 20;19(31):3521-8. doi: 10.1038/sj.onc.1203698. Oncogene. 2000. PMID: 10918610

10

ARG tyrosine kinase activity is inhibited by STI571.

Okuda K, Weisberg E, Gilliland DG, Griffin JD. Okuda K, et al. Among authors: griffin jd. Blood. 2001 Apr 15;97(8):2440-8. doi: 10.1182/blood.v97.8.2440. Blood. 2001. PMID: 11290609 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

544 results

Search Page

Filters